Enhancer of Zeste Homolog 2 Protein
"Enhancer of Zeste Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation at the PROMOTER REGIONS of the circadian genes and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.
| Descriptor ID |
D000071221
|
| MeSH Number(s) |
D05.500.781.750.250 D08.811.913.555.500.800.400.500.500 D12.776.660.235.600.200.250 D12.776.664.235.800.200.250 D12.776.930.780.890.200.250
|
| Concept/Terms |
Enhancer of Zeste Homolog 2 Protein- Enhancer of Zeste Homolog 2 Protein
- Lysine N-Methyltransferase-6
- Lysine N Methyltransferase 6
- Histone-Lysine N-Methyltransferase EZH2
- EZH2, Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase EZH2
- Enhancer of Zeste Homolog 2
|
Below are MeSH descriptors whose meaning is more general than "Enhancer of Zeste Homolog 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Enhancer of Zeste Homolog 2 Protein".
This graph shows the total number of publications written about "Enhancer of Zeste Homolog 2 Protein" by people in this website by year, and whether "Enhancer of Zeste Homolog 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 5 | 5 | 10 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 3 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enhancer of Zeste Homolog 2 Protein" by people in Profiles.
-
EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. Stem Cell Reports. 2024 10 08; 19(10):1516.
-
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer. Br J Cancer. 2024 Jul; 131(1):171-183.
-
Telomere dysfunction alters intestinal stem cell dynamics to promote cancer. Dev Cell. 2024 Jun 03; 59(11):1475-1486.e5.
-
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Hum Pathol. 2024 04; 146:1-7.
-
E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. J Exp Med. 2024 Apr 01; 221(4).
-
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 12 01; 83(23):3956-3973.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023 10; 37(10):2094-2106.
-
A de novo missense variant in EZH1 associated with developmental delay exhibits functional deficits in Drosophila melanogaster. Genetics. 2023 08 09; 224(4).
-
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice. Arthritis Rheumatol. 2023 08; 75(8):1395-1406.